AV Therapeutics — Investor Presentation (January 2015)
19 slides from AV Therapeutics's investor presentation, Jan 16, 2015

Slide 1: Capridine-B: Novel Chemotherapies for Advanced Prostate Cancer
Id CAPRIDINE-8 (c-1748) Novel Chemotherapies for Advanced Prostate Cancer Patients in Stages 2-4 y \f AV Therapeutics, Inc. ‘Advanced Canna Chanahorgies

Slide 2: Safe Harbor Statement
Safe Harbor Stateme “This presentation has been prepared for informational purposes only and does nct constitute an aff or soliton to buy secuntis in AV Therapeutic. (the “Company” {anditssubsigiaes including but not limited to AV Therapeutics, Inc) Any such offeror solisttion wil be made only by me

Slide 3: Capital Market Snapshot
Capital Market Snapshot OTCQB Year Incorporated: 2011 Shares Outstans “2M Price Range (4/1/14 — 12/31/14): $0.39. $0.04 Market Capitalization(4/1/14-12/31/14): $30.0-$4.0 M Average Volume: 76,055 Year End: December 31* Offices: New York Legal: SRF, New York Auditor: Marcum, New York Trading History—

Slide 4: Drs. Mittelman and Tiwari's collaboration in cancer research
Drs. Mittelman and Tiwari’s collaboration in cancer research dates back to 1996 at Memorial Sloan Kettering Cancer Center. Their combined experience includes 60+ years of research and more than 300 = published research articles in cancer chemotherapy and immunotherapies lead to the discovery of Capr

Slide 5: Prostate Cancer
Prostate Cancer The Second Leading Cause of Cancer Deaths in Men The Facts. Prostate cancer is the most common cancer in American men after skin cancer. * About 233,000 new cases of prostate cancer will be diagnosed * About 29,480 men will die of prostate cancer * About 1 man in 6 will be diagnosed

Slide 6: Treatment Challenges
eatmen allenge: |. Limited Efficacy for Metastatic Disease Radiation, hormonal and chemotherapy remain palliative and development of resistance is very common é. High Toxicity Severe bone marrow toxicity and poortolerance Hormone Interdependence PCa initiates as hormone sensitive and develops into a

Slide 7: Clinical States and Stages in Prostate Cancer
Clinical States and Stages in Prostate Cancer STAGE1 STAGE 2 STAGE 3 STAGE 4 Stage 1: Surgery and radiation or watchful waiting : Stage 2-4: Limited chemotherapy options, all drugs besides Taxotere and Cabizataxel are in the antihormone area of treatment. In patients who are resistant, only the two

Slide 8: Current Drug Therapies in Use
Current Drug Therapies in Use During Critical States and Throughout Stages srace 1 sTace2 srace 3 srace4 R os =) a Abiraterone R ME Rad 233 ovsi00 rl Den R ib ae ca aa an ‘Sipuleucel-T Le ae CAPRIDINE-3 <—$— $a << << <> Capridine- can provide consistenttreatment though Stages 2-4 y\'}

Slide 9: NCI Test Data
NCI Test Data Capridine-c. Shows PCa Specificity in Addition to Benefits for Many Cancers ‘smal Cll Lung Cancer

Slide 10: AV Therapeutics Patents on Capridine
AV Therapeutics Patents on Capridine 2 Patentsissued 1 Patent pending 200 Derivatives allowed 2 Exclusive rights to patents —_——<== = <= |= | capri Stes CepinConponen | Fete ea g — diseases and Fal Cae] Immunotherapy for 200 Derivatives of Beale Coron Guctn Capridine Synthesis expressing prosate spe

Slide 11: Capridine-B Kills Prostate Cancer Preferentially
Capridine-f Kills Prostate Cancer Preferentially U-145 Cals Treated with Capridine- I-60 Cells Tested with Capricine- fy a ~ E H i i ge ge i 1 bo concentration fa i) : zncentrton of Oa *: Prostate cancer cells (DU-145) are 10 to 100-fold more sensitive to Capridine-f than leukemic cells (HL-60). 7 \

Slide 12: Capridine-B and Hormone Independence
Capridine-B and Hormone Independence Typical Loss of Androgen Receptor ine-B renders Hormone-Independent Early Step in Prostate Tumor Progression DU-145 PCa Cells Hormone-Sensitive sree . ee i — a z Androg ptor : i 2 3 Induction of Androgen Receptor in DU-145 Cells ai — — fom oe pee go|—_» § 9 9 * T

Slide 13: Capridine-B Inhibits Hormone-Responsive and Non-Responsive Xenografts in Nude Mice
Capridine-B Inhibits Hormone-Responsive and Non- Responsive Xenografts in Nude Mice tect of Copa, inhibit the gronth of PC-3 Hfect of Cap, Binkibit the growth of ln Cap enogras in nude mice enograts in nade mice ia en oeEbEEEROE Th Htc f Capa, inhibit the growth of CA ‘ems Bec of erent doses of Cap

Slide 14: Activity of Capridine vs. Taxane in PCa Cells
Activity of Capridine vs. Taxane in PCa Cells LnCapa hormone dependent cell is resistantto Taxane but sensitive to Capridine. Bothhormone dependent (LnCap) and refractory (PC-3 and DU145) are sensitive to Capridine. WA * Celttines laarnnierae CAPRIDINE-8 ‘Taxane Capridine (c-1748) ba LncaP >100nM 15

Slide 15: Capridine-B Advantage Summary
Capridine-6 Advantage Summary 1. NCI Tested, Prostate Cancer Specific 4. High therapeutic index for prostate (Over 6.5 milion dollars invested in development (pre- Low amount of drug, high efficacy. Wide, predicted human AVT) - Needto dedicate side therapeutic dose range 2. Patent Protected 5. Activ

Slide 16: Management Team
> am Mittelman, M.D. aac el) | chiet executive officer and chairman ofthe Board seal Gaffe) Oncologst and Associate Prot. t New York Medica Sera ies explénce:oundieand College (NYMC) with over 30 years of experiencein managing partner of Continuum Partners, a global network patient treatment and cli

Slide 17: Broad-based IP of Capridine Provides Additional Near-Term Opportunities
Broad-based IP of Capridine Provides Additional Near-Term Opportunities Capridine-B is also a Potent Anticancer Drug se en Cyy Value Results Demonstrated in Several Cancers — Colon and Sarcoma 500) |) “Cepione no sex More Effector + Capridine is highly effective for prostate cancers but can fo Conca

Slide 18: Why Invest in AVTH
Why Investin AVTH 1. Our preciinical studies are complete for Capridine. More than $6.5 millionhas been invested in AV Therapeuticsto date. 2. Our formulation of Capridine include no blood toxicity and wide therapeutic doserangewith specificity towards prostate cancer. 3. We are ready to commence ph

Slide 19: Contact Us
Contact Us AV Therapeutics, Inc. “Advaneed Canc Chanathpies EXECUTIVE: Dr. Abraham Mittelman, M.D. Tel: 1-914-588-4666 Email: am@avth.net Headquarters: SCIENCE: Dr. Raj Tiwari, Ph.D. Tel: 646-662-6439 Email riwari@avth.net 20 East 68th Street Suite 204 New York , NY 10065 United States www.avth.net
Source: SEC EDGAR · 8-K filed Jan 16, 2015
